|2.||Neoplasm Metastasis (Metastasis)
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|4.||Breast Neoplasms (Breast Cancer)
|1.||Minna, John D: 104 articles (12/2015 - 01/2002)|
|2.||Boffetta, Paolo: 93 articles (01/2016 - 01/2002)|
|3.||Mitsudomi, Tetsuya: 83 articles (01/2016 - 04/2002)|
|4.||Zhou, Qinghua: 79 articles (09/2015 - 02/2002)|
|5.||Wistuba, Ignacio I: 72 articles (05/2015 - 10/2002)|
|6.||Kiura, Katsuyuki: 71 articles (08/2015 - 01/2002)|
|7.||Yatabe, Yasushi: 70 articles (12/2015 - 01/2002)|
|8.||Yang, Pan-Chyr: 68 articles (12/2015 - 11/2002)|
|9.||Spitz, Margaret R: 67 articles (05/2015 - 01/2002)|
|10.||Gazdar, Adi F: 66 articles (11/2015 - 01/2002)|
|1.||Cisplatin (Platino)FDA LinkGeneric
01/01/2015 - "The extent of proliferation inhibition induced by cisplatin after knockdown of FANCF and/or FANCL in A549/DDP cells was significantly greater than in A549 and SK-MES-1 cells, suggesting that depletion of FANCF and/or FANCL can reverse resistance of cisplatin-resistant lung cancer cells to cisplatin. "
10/01/2006 - "Furthermore, a systemic treatment with a combination of NPRL2 nanoparticles and cisplatin in a human H322 lung cancer orthotopic mouse model significantly enhanced the therapeutic efficacy of cisplatin and overcame cisplatin-induced resistance (P < 0.005). "
01/01/2014 - "The major aim of this effort was to evaluate whether Cisplatin-Encapsulated magnetic nanoparticles improved the anti-tumour effect of free Cisplatin in lung cancer cells. "
07/01/1985 - "The results show that the combination of cisplatin and 60Co therapy is more effective for the advanced lung cancers."
06/01/2013 - "Cisplatin is widely used for the treatment of solid tumours including small cell lung cancers, but its success is often compromised by relapse and resistance to further treatment. "
|2.||Epidermal Growth Factor Receptor (EGF Receptor)IBA
09/01/2013 - "A minimally invasive and repeatable approach for real-time epidermal growth factor receptor (EGFR) mutation surveillance would be highly beneficial for individualized therapy of late stage lung cancer patients whose surgical specimens are often not available. "
01/01/2014 - "The high efficacy of crizotinib in ALK- and ROS-positive lung cancer as new molecular targets beside the epidermal growth factor receptor (EGFR) underscores the importance of molecular typing in NSCLC."
06/01/2015 - "Epidermal growth factor receptor (EGFR) mutations can affect the therapeutic efficacy of drugs used to treat nonsmall-cell lung cancer (NSCLC). "
07/01/2011 - "Preclinical results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors. "
07/15/2006 - "Inhibitors targeting the epidermal growth factor receptor (EGFR) are effective in a subset of non-small cell lung cancers. "
|3.||gefitinib (Iressa)FDA Link
03/15/2014 - "Our data suggest additive rather than synergistic interactions between gefitinib and radiation and that a combination of short-course gefitinib and high-dose/-fraction radiation may have the greatest potential against the subsets of lung cancers harboring activating mutations in the EGFR gene."
01/01/2011 - "Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?"
04/01/2004 - "EGFR mutants render Iressa more effective in treating lung cancer."
03/15/2014 - "Taken together, our findings suggest a novel insight that EGFR endocytosis is a rational therapeutic target in lung cancer with wtEGFR, in which the combined efficacy with gefitinib is expected. "
02/01/2011 - "Although gefitinib is known to possess an effect inducing apoptosis against lung cancer, it is not clear how clinically effective it is in this regard in patients with lung cancer. "
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/01/2009 - "Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. "
08/01/2011 - "Upfront tyrosine kinase inhibitor (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. "
10/01/2011 - "Given the unprecedented efficacy of EGFR tyrosine kinase inhibitors (TKI) in advanced EGFR-mutant lung cancer, adjuvant TKI therapy is an appealing strategy. "
07/26/2011 - "Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors."
01/01/2011 - "We have discovered a small, fusion-type tyrosine kinase EML4-ALK that is generated through a tiny inversion within the short arm of human chromosome 2. Transgenic mice expressing EML4-ALK in lung developed hundreds of lung cancer nodules soon after birth, but such nodules were readily eradicated upon treatment with an ALK inhibitor. "
|5.||Paclitaxel (Taxol)FDA LinkGeneric
04/26/2001 - "We conclude that taxol is effective in inducing apoptosis at very low doses (0.020-0.035 microM), and that the presence or absence of the wild-type p53 does not make a statistically significant difference in the level of apoptotic cell death in these lung cancer cell lines, but the maximum is attained at a lower drug concentration in the presence of p53."
01/25/2006 - "somnifera along with paclitaxel which is found to be more effective in the treatment of lung cancer. "
01/01/2012 - "Our results reveal that activation of NAG-1 by K8 enhanced the therapeutic efficacy of paclitaxel in human lung cancer cells via the ERK1/2 signaling pathway."
04/15/1994 - "Taxol is a novel antitumor agent with demonstrated efficacy against ovarian, breast, and non-small cell lung cancers in Phase II clinical trials, but which has been shown not to cross the blood-brain barrier. "
04/01/2011 - "Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation."
|6.||erlotinib (CP 358,774)FDA Link
09/01/2006 - "The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC). "
11/17/2015 - "Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer."
08/20/2006 - "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21."
08/15/2014 - "In addition, moderate clinical efficacy of the EGFR-TKI, erlotinib, has been shown in lung cancer patients with the wild-type EGFR. "
01/01/2012 - "Several clinical and biological parameters are known to influence the efficacy of second-line erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact has not been evaluated. "
|7.||Biological Markers (Surrogate Marker)IBA
07/01/2005 - "Improvement in the performance of sputum, exhaled breath, or blood biomarkers holds promise as the first screening step to identify individuals at highest risk of lung cancer beyond what age and smoking could predict to select those who would obtain the most benefits from spiral computed tomography or autofluorescence bronchoscopy as localization tools."
01/01/2014 - "The survival rate of lung cancer can be significantly improved by monitoring biomarkers in exhaled air that indicate diseases in early stage, so it is very important to develop micro analytical systems which can offer a fast, on-site, real-time detecting biomarkers in exhaled air. "
12/01/2004 - "The recent introduction of biomarkers in population studies of lung cancer has improved the traditional epidemiological approach, especially in the detection of high risk groups. "
09/01/2014 - "Future validation of all the candidates defined by shotgun proteomics in a large cohort study may help develop additional biomarkers that can be added to ENO1 to provide more diagnostic efficacy for lung cancer."
04/11/2005 - "We performed a clinical study to identify biological markers useful for the treatment of resectable non-small-cell lung cancers (NSCLCs). "
|8.||docetaxel (Taxotere)FDA Link
01/15/2009 - "These findings suggest potential benefit for use of docetaxel and DIM-C-pPhC(6)H(5) combination in lung cancer treatment."
11/01/2010 - "The purpose of this study was to determine the anticancer efficacy of 1,1-bis (3'-indolyl)-1-(p-biphenyl) methane (DIM-C-pPhC₆H₅) by inhalation delivery alone and in combination with i.v. docetaxel in a murine model for lung cancer. "
03/01/2015 - "In this study, this laboratory detected that DNA methylation contributes to the downregulation of DKK3 in docetaxel resistance of human lung cancer cells and its possible biochemical mechanism. "
01/01/2015 - "This study was to investigate inhibiting effect of structurally unique Second mitochondria-derived activator of caspase (Smac) in combination with Docetaxel on lung cancer cell line A549. "
01/01/2014 - "In the current study, we established a new docetaxel-resistant human non-small lung cancer (NSCLC) cell line A549/Docetaxel. "
|9.||Carboplatin (JM8)FDA LinkGeneric
01/01/1998 - "A total of 52 patients with advanced lung cancer were enrolled in this pharmacokinetic study; 37 received standard-dose carboplatin and 25 received low-dose carboplatin. "
08/01/1990 - "A Phase II trial of carboplatin (CBDCA) was performed in 33 patients with advanced lung cancer, including 15 patients with inoperable Stage III non-small-cell (NSCLC) and 18 patients with relapsed small-cell (SCLC) lung cancer. "
01/01/1990 - "Phase II study of carboplatin in patients with nonresected lung cancer. "
04/01/1989 - "Review of therapeutic trials of carboplatin in lung cancer."
09/01/1988 - "A phase II study of carboplatin in ready-to-use solution (RTU) was conducted in patients with primary lung cancer at 9 institutes throughout Japan. "
05/01/2009 - ": Although platinum-based combinations are considered the best option of care for patients with advanced nonsmall cell lung cancer (NSCLC), single-agent therapy is the preferred treatment for older patients. "
02/01/2002 - "These agents may be particularly useful in the treatment of lung cancer, both as adjunctive therapy in early-stage or locally advanced disease, as well as in combination strategies with platinum-based therapy in metastatic disease. "
09/22/2015 - "Our previous study identified that it was correlated with platinum response in lung cancer. "
03/01/2014 - "Confocal fluorescence microscopy was used to study a platinum-based anticancer agent in intact NCI-H460 lung cancer cells. "
01/01/2013 - "The large LUX-Lung 3 phase III trial recently reported afatinib to be clearly superior over the most effective platinum doublet in patients with EGFR mutation-positive lung cancer. "
|1.||Drug Therapy (Chemotherapy)
03/01/2003 - "In conclusion, chemotherapy results in a modest, but significant improvement in survival in patients with inoperable lung cancer compared to best supportive care alone."
12/01/1987 - "While waiting for the development of new and more active drugs for lung cancer chemotherapy, the innovative investigation of the best drugs currently available provides the best chance for improved results."
12/08/2011 - "Furthermore, there are evidences that various herbal medicines have proven to be useful and effective in sensitizing conventional agents, prolonging survival time, preventing side effects of chemotherapy, and improving quality of life (QoL) in lung cancer patients. "
07/01/2010 - "While, according to the "clinic efficacy appraisal standard of therapy for advanced lung cancer with CM", the efficacy of the CM group was better than that of the chemotherapy group without statistical difference (P = 0.05), however, there was a very strong trend of appearing difference. "
01/16/2006 - "The analysis demonstrates that there has been a significant improvement in survival for elderly patients with lung cancer treated by chemotherapy in the past 20 years despite more very elderly patients being treated with a poorer performance status. "
01/01/2015 - "Eventually, this may help to truly individualize radiotherapy, using a personal genetic profile of the most relevant genes for each lung cancer patient. "
01/01/2013 - "Is radiofrequency ablation or stereotactic ablative radiotherapy the best treatment for radically treatable primary lung cancer unfit for surgery?"
06/01/2010 - "Minimally invasive local treatment modalities including dose-intensified conformal radiation therapy, most notably stereotactic ablative radiotherapy (SABR; also known as stereotactic body radiation therapy), and thermal ablation methods such as radiofrequency ablation (RFA) and microwave ablation (MWA) are emerging as promising treatment options whose roles in the treatment of early stage lung cancer are being defined. "
12/01/2011 - "MI can enhance the efficacy of radiotherapy with different therapeutic schedules in mice bear Lewis lung cancer, and MI plus fractionated radiation produces the optimal effect."
12/01/2007 - "The results suggest that rhK5 significantly enhances the antitumor activity of RT and could be a potent adjuvant therapeutic approach to improve the efficacy of radiotherapy for lung cancer."
|3.||Heterologous Transplantation (Xenotransplantation)
10/01/2010 - "In vivo studies revealed that the combination of NK012 plus Bv had significantly greater antitumor activity against human lung cancer xenografts compared with NK012 alone (PC-14, P=.0261; A549, P<.001). "
11/01/2012 - "The efficacy of the CpG-enriched virus was assessed in a xenograft model of lung cancer where a significant increase in antitumor effect was seen in comparison with controls. "
10/01/2002 - "We have previously shown successful therapy in a lung cancer xenograft model using an adenovirus expressing antisense IGF-Ir. "
07/01/2001 - "Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine."
01/01/2011 - "Furthermore, the combination was also more effective than either agent alone in inhibiting the growth of lung cancer xenografts in mice. "
01/01/2014 - "This review discusses the preclinical and clinical development of tecemotide, ongoing preclinical studies of tecemotide in human MUC1 transgenic mouse models of breast and lung cancer, and the potential application of these models for optimizing the timing of chemoradiotherapy and tecemotide immunotherapy to achieve the best treatment outcome for patients. "
03/01/2015 - "With multiple studies under way, there are high expectations that treatment outcomes in patients with lung cancer who are ineligible for complete surgical resection may be improved with the incorporation of immunotherapies in the various treatment cascades. "
08/01/1981 - "A prospective, randomized trial is planned to determine whether BCG immunotherapy will result in significantly improved survival in patients with primary and metastatic pulmonary neoplasms."
08/01/2012 - "In conclusion, the results suggest that immunotherapy regimen targeting CTLA-4 and Treg cells might be beneficial in lung cancer patients."
08/15/1984 - "In conclusion, TF seems to suppress postoperative recurrence and appears to be beneficial for primary resected lung cancer patients, especially at early stages, as postoperative adjuvant immunotherapy."
05/01/2009 - "No chemoprevention strategies have been proven effective for lung cancer. "
08/01/2003 - "A major challenge in this regard is the development of safe and effective lung cancer chemoprevention. "
11/01/2013 - "Research has shown that chemoprevention may be effective against the development of lung cancer. "
09/01/2010 - "No clinically effective chemoprevention for lung cancer has been found. "
09/01/2008 - "treatment with NNK and 12 weeks duration are effective for detection of lung cancer chemoprevention in our A/J mouse lung tumorigenesis model."